Tyler Van Buren
Stock Analyst at TD Cowen
(3.01)
# 1,432
Out of 4,711 analysts
60
Total ratings
41.67%
Success rate
1.96%
Average return
Main Sectors:
Stocks Rated by Tyler Van Buren
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KROS Keros Therapeutics | Downgrades: Hold | n/a | $17.03 | - | 2 | Dec 12, 2024 | |
| BHVN Biohaven | Maintains: Buy | $55 → $75 | $36.26 | +106.84% | 2 | Nov 13, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Buy | n/a | $17.59 | - | 1 | Oct 8, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Buy | n/a | $20.31 | - | 1 | Sep 16, 2024 | |
| MRNA Moderna | Maintains: Hold | $70 → $60 | $39.39 | +52.32% | 6 | Sep 13, 2024 | |
| ARTV Artiva Biotherapeutics | Initiates: Buy | n/a | $11.11 | - | 1 | Aug 13, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | n/a | $19.02 | - | 1 | Aug 6, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,030 → $1,200 | $701.85 | +70.98% | 7 | Jul 23, 2024 | |
| TECX Tectonic Therapeutic | Initiates: Buy | n/a | $47.44 | - | 1 | Jun 24, 2024 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Buy | n/a | $25.50 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $85 | $92.57 | -8.18% | 5 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $40.72 | -26.33% | 2 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $14.90 | - | 1 | Dec 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $23.86 | - | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $75.54 | - | 1 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $47.71 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.15 | - | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $17.18 | +74.62% | 1 | May 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $26.49 | - | 1 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.68 | - | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $70 | $28.33 | +147.13% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.00 | - | 1 | Jul 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $18.48 | - | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $14.00 | - | 1 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $1.60 | +3,025.00% | 1 | Mar 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $875 | $39.84 | +2,096.29% | 1 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $185 | $176.50 | +4.82% | 3 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $2.99 | +1,237.79% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $19.83 | +101.71% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $30 | $9.59 | +212.83% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $9.45 | +217.46% | 1 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $2.91 | +1,961.86% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $13.21 | +278.50% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $0.84 | +3,471.43% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $140 → $200 | $4.74 | +4,119.41% | 1 | Jan 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $10.31 | - | 1 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $22.09 | - | 1 | Aug 4, 2017 |
Keros Therapeutics
Dec 12, 2024
Downgrades: Hold
Price Target: n/a
Current: $17.03
Upside: -
Biohaven
Nov 13, 2024
Maintains: Buy
Price Target: $55 → $75
Current: $36.26
Upside: +106.84%
Bicara Therapeutics
Oct 8, 2024
Initiates: Buy
Price Target: n/a
Current: $17.59
Upside: -
Oruka Therapeutics
Sep 16, 2024
Initiates: Buy
Price Target: n/a
Current: $20.31
Upside: -
Moderna
Sep 13, 2024
Maintains: Hold
Price Target: $70 → $60
Current: $39.39
Upside: +52.32%
Artiva Biotherapeutics
Aug 13, 2024
Initiates: Buy
Price Target: n/a
Current: $11.11
Upside: -
Cartesian Therapeutics
Aug 6, 2024
Initiates: Buy
Price Target: n/a
Current: $19.02
Upside: -
Regeneron Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $1,030 → $1,200
Current: $701.85
Upside: +70.98%
Tectonic Therapeutic
Jun 24, 2024
Initiates: Buy
Price Target: n/a
Current: $47.44
Upside: -
NewAmsterdam Pharma Company
May 15, 2024
Initiates: Buy
Price Target: n/a
Current: $25.50
Upside: -
Apr 26, 2024
Maintains: Buy
Price Target: $90 → $85
Current: $92.57
Upside: -8.18%
Dec 11, 2023
Downgrades: Underperform
Price Target: $30
Current: $40.72
Upside: -26.33%
Dec 5, 2023
Initiates: Outperform
Price Target: n/a
Current: $14.90
Upside: -
Nov 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $23.86
Upside: -
Oct 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $75.54
Upside: -
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $47.71
Upside: -
May 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $3.15
Upside: -
May 22, 2023
Initiates: Outperform
Price Target: $30
Current: $17.18
Upside: +74.62%
Feb 6, 2023
Initiates: Outperform
Price Target: n/a
Current: $26.49
Upside: -
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.68
Upside: -
Aug 8, 2022
Initiates: Outperform
Price Target: $70
Current: $28.33
Upside: +147.13%
Jul 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $3.00
Upside: -
Dec 7, 2021
Initiates: Outperform
Price Target: n/a
Current: $18.48
Upside: -
Oct 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $14.00
Upside: -
Mar 4, 2021
Initiates: Overweight
Price Target: $50
Current: $1.60
Upside: +3,025.00%
Nov 10, 2020
Initiates: Overweight
Price Target: $875
Current: $39.84
Upside: +2,096.29%
Nov 6, 2020
Downgrades: Underweight
Price Target: $185
Current: $176.50
Upside: +4.82%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $2.99
Upside: +1,237.79%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $19.83
Upside: +101.71%
Aug 10, 2020
Maintains: Overweight
Price Target: $35 → $30
Current: $9.59
Upside: +212.83%
Aug 4, 2020
Initiates: Overweight
Price Target: $30
Current: $9.45
Upside: +217.46%
Jun 29, 2020
Initiates: Overweight
Price Target: $60
Current: $2.91
Upside: +1,961.86%
Jun 29, 2020
Initiates: Overweight
Price Target: $50
Current: $13.21
Upside: +278.50%
Apr 22, 2020
Initiates: Overweight
Price Target: $30
Current: $0.84
Upside: +3,471.43%
Jan 13, 2020
Reiterates: Overweight
Price Target: $140 → $200
Current: $4.74
Upside: +4,119.41%
Nov 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $10.31
Upside: -
Aug 4, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $22.09
Upside: -